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Resistance in viruses other than HIV 
Paul D. Griffiths 
The aim of this brief paper is to summarize the ways in which viruses develop resistance to currently licensed anti- 
viral drugs and to comment on their clinical relevance. Specific examples will be chosen to emphasize basic principles 
of the development of resistance and readers are referred elsewhere to a summary of resistance in HIV that follows 
the same princip1es.l 
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OBJECTIVES OF ANTIVIRAL DRUG 
DISCOVERY 
The decision to develop an antiviral compound against 
a particular virus starts with the adoption of that virus 
as a valid target for the pharmaceutical industry. This 
includes assessment of a business case and also the 
importance of the pathogen in terms of the number of 
individuals affected and the severity of disease. Once a 
particular virus has been adopted as a target, its viral 
replication strategy will be examined to identify a 
particular biochemical step that may be amenable to 
interference. Ideally, such a virus-encoded enzyme 
should be essential for the viral replicative cycle, so that 
a virus with the enzyme deleted should be incapable 
of replication. Having identified a particular enzyme 
target, novel chemical entities are then screened for 
their ability to inhibit the enzymic process. Once a lead 
compound has been identified, extensive chemical 
modifications are required to turn this inhibitor into a 
practical drug in terms of potency, potential safety, bio- 
availability and pharmacokinetics. 
Once a lead compound has been identified for 
clinical trial, the focus is on safety, efficacy and dose- 
optimisation as it makes its way through phase I and 
phase II trials. Once the drug reaches phase III 
development, assays to detect resistance are increasingly 
being incorporated. In some cases, the detection of 
resistant strains can lead to a lack of confidence in the 
compound’s ability to become a useful new drug. 
However, it must be emphasized that the detection of 
resistance is always good news, and may only be bad 
news once a particular set of circumstances have been 
proven to occur (see Table 1). Thus, the detection of 
resistance is relatively straightforward, whereas the 
clinical significance of that resistance may be extremely 
complex to elucidate. 
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HERPES SIMPLEX AND ACYCLOVIR 
Herpes simplex virus (HSV) is an alpha herpes virus 
that establishes latency in the dorsal root ganglia of the 
trigeminal nerve (typically HSV-1) or sacral nerves 
(typically HSV-2). In order to reactivate, it requires the 
biochemical precursors of DNA, but the dorsal root 
ganglion is terminally differentiated and so has a low 
natural content of nucleotides. During its evolution to 
become a successful infectious agent, HSV has therefore 
acquired genes for the anabolism of nucleotides. The 
first of these is ribonucleotide reductase, which scavenges 
nucleotides from the breakdown of RNA into the DNA 
pathway. The second is thymidine kinase (Tk), which 
takes nucleosides such as thymidine or guanosine and 
phosphorylates them to the monophosphate. Cellular 
enzymes then complete the conversion of these entities 
to the nucleoside triphosphate, which is required for 
DNA anabolism. The third is the virus-encoded DNA 
polymerase, which takes the nucleoside triphosphates to 
form the DNA polymer comprising the HSV genome. 
Acyclovir is a substrate for the virus-induced thymi- 
dine kinase (but not the cellular thymidine kinase). 
Once acyclovir monophosphate has been formed in this 
way, cellular enzymes convert it to the triphosphate form 
in which it acts as a potent competitive and suicide 
inhibitor of the HSV DNA polymerase. If small amounts 
of acyclovir are phosphorylated in uninfected cells, the 
triphosphate is formed by cellular enzymes but is a very 
poor inhibitor of the cellular DNA polymerase. Thus, the 
exquisite selectivity of acyclovir for HSV-infected cells 
resides in two enzymes: the virus-encoded thymidine 
kinase and the virus-encoded DNA polymerase. 
It is evident that HSV has a strong selective 
pressure placed upon it at the Tk and DNA polymerase 
loci by exposure to acyclovir.z The easiest way for the 
virus to deal with acyclovir is to stop producing the Tk 
enzyme. It can do this by individual point mutations, 
which introduce premature stop codons, thereby pro- 
ducing a truncated and enzymically ineffective Tk 
(termed Tk- strain). Such stop codons can be selected 
for at several positions in the gene, so that Tk- strains of 
virus are genetically heterogeneous. Alternatively, 
specific mutations can occur that reduce the affinity of 
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the Tk for acyclovir while allowing the natural substrate 
still to be accepted (termed Tk alt [altered] strain). 
Finally, mutations can occur in the DNA polymerase 
that reduce the inhibitory effect of acyclovir tripho- 
sphate while still allowing the enzyme to accept natural 
nucleoside triphosphates as substrates (termed DNA 
pol strain). 
The Tk-mutants occur frequently, but fortunately 
replicate very poorly (as a result of the lack of Tk) and 
are profoundly debilitated in terms of neuropathology 
and peripheral replication when examined in mouse 
models. In addition, they have an impaired ability to 
establish latency and cannot reactivate.3 In contrast, 
the Tk- alt and the DNA pol mutations produce viruses 
with nearly 100% wild-type pathogenicity.2 It is fortun- 
ate therefore that the latter two mutants are very 
uncommon in clinical practice, and that virtually all 
strains seen in patients are of the Tk- variety. The 
profoundly debilitated phenotype of the Tk- strains 
explains why suppressive acyclovir can be given for 
many years to individuals without the development of 
clinically significant resistance.4,5 Nevertheless, we 
should also recognize that pathogenicity is a relative 
concept so that Tk- viruses can cause disease in pro- 
foundly immunocompromised patients, despite their 
debilitation. Thus, the first description of clinically 
significant resistance in HSV was in AIDS patients.6 
Tk- strains of virus are cross-resistant to ganciclovir 
because of its structural similarity to acyclovir. However, 
Tk- strains are usually sensitive to foscarnet and to 
vidarabine. A clinical trial was therefore conducted to 
compare foscarnet with vidarabine for the treatment of 
Tk- strains of HSV in AIDS patients who were un- 
responsive to intravenous acyclovir. Although it was a 
small trial, all eight patients randomized to foscarnet 
showed healing compared to O/6 randomized to vidara- 
bine.7 This study established foscarnet as the treatment 
of choice for strains of HSV resistant to acyclovir. 
As expected from the natural history described 
above, the initial recurrences of HSV in patients treated 
with foscarnet are once again sensitive to acyclovir 
because it is the wild type that reactivates from the 
Table 1. Identification of Antiviral Resistance in a Patient can 
be both Good and Bad News 
Good news Confirmation that the drug targets a virus- 
specific process 
Identification of molecular target 
Implication of target as a component of 
selectivity 
Provision of mutants for pathogenicity studies 
Provision of a genetic marker for resistance 
which could be useful clinically 
Bad news Mutant may still be pathogenic 
Patient may fail to respond to treatment 
Alternative therapy may be toxic and/or 
expensive 
Mutant strain may spread to other patients 
dorsal root ganglia. However, the process of selection 
via common point mutations can then repeat itself so 
that another Tk-strain of HSV may appear, requiring 
treatment of the patient with another course of foscarnet. 
Any lesions that recur in a patient who has received 
foscarnet should therefore be cultured to detect HSV 
resistance to acyclovir. An audit of a clinicopathological 
analysis of such testing for resistant strains shows a 
strong correlation between detection of resistance in the 
laboratory and the failure of acyclovir to heal the clinical 
lesion.8 Unfortunately, ongoing virus replication in the 
presence of foscarnet leads to resistance (which maps to 
DNA polymerase) and so such patients should also be 
examined for foscarnet sensitivity.8 
At the time of writing, HSV-resistant strains have 
become uncommon again as a result of the availability 
of highly active antiretroviral therapy (HAART). This 
emphasizes that Tk-strains have greatly reduced 
pathogenicity and should be predicted to cause disease 
only in individuals who are profoundly immunocom- 
promised. Nevertheless, one should remain vigilant in 
patients who have failed HAART and consider the 
possibility of acyclovir-resistant strains when any patient 
fails to respond to this drug. The usual protocol is to 
check the patient’s compliance with the prescribed 
acyclovir and, if this appears satisfactory, swap them to 
intravenous acyclovir to exclude the possibility of poor 
gastrointestinal absorption. If there is still no response, 
cultures should be taken for resistance testing and the 
patient given foscarnet if a resistant strain is detected. 
Strains resistant to foscarnet should be treated with 
cidofovir, although not all respond clinically.9 
CMV AND GANCICLOVIR 
Ganciclovir works against cytomegalovirus (CMV) in an 
entirely analogous way to acyclovir in HSV-infected 
cells. The virus-encoded enzyme that performs the 
initial phosphorylation is UL97, a protein kinase 
encoded by the 97th gene in the unique long region of 
CMV.‘O,ll It phosphorylates ganciclovir or acycloviP to 
their monophosphates and cellular enzymes convert 
these moieties to their triphosphates. Both ganciclovir 
triphosphate and acyclovir triphosphate are potent 
inhibitors of CMV-encoded DNA polymerase.13 This 
explains why both ganciclovir and acyclovir can be 
used for prophylaxis after transplant.r&l6 However, 
ganciclovir is definitely more potent in vitro than 
acyclovir, and the same may be true in vivo, perhaps 
because of the longer intracellular half-life of ganciclovir 
triphosphate. This deficiency in the case of acyclovir 
can be partially overcome by increasing the dose by 
using the valaciclovir prodrug and high doses of this 
compound have recently shown excellent control of 
CMV disease following renal transplantation.17 Never- 
theless, the early work on the action of acyclovir against 
CMV18 was virtually ignored and so most clinical experi- 
ence has been gained with ganciclovir, and, as a 
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result, most clinical experience of resistance is also with 
ganciclovir. 
The selective pressure on CMV is through genes 
UL97 and DNA polymerase and, by analogy with 
HSV, most strains are resistant because of mutations in 
UL97. If CMV replication continues in the presence of 
ganciclovir, then additional mutations may be selected 
in the DNA polymerase. Some of these may be cross- 
resistant to cidofovir and/or foscarnet, thereby removing 
all practical options for treating resistant strains.19 It is 
therefore imperative that patients with suspected CMV 
infection are treated promptly and intensively to reduce 
the chance of resistance developing. Both prophylaxis 
from the time of transplant onwards and pre-emptive 
therapy (giving ganciclovir to a patient in whom 
laboratory markers show evidence of active CMV infec- 
tion) are effective treatment options, although the 
relative merits of each are hotly debated.20J1 
In clinical practice, molecular methods can be used 
to detect resistant strains directly from clinical material. 
This is far superior to the time-consuming approach of 
passing CMV in cell cultures and performing classic 
plaque reduction assays. In patients receiving long-term 
ganciclovir (especially oral ganciclovir, which is poorly 
bioavailable) resistant strains can be detected fairly 
frequently; for example, during follow-up of 45 AIDS 
patients with CMV retinitis who received ganciclovir 
maintenance therapy, we detected resistance in 22%.22 
By using quantitative assays to follow the evolution of 
these strains, it has been possible to calculate their fitness 
differences as well as the dynamics of CMV replication 
in vivo.23 Overall, although they include different point 
mutations and/or deletions within gene UL97, these 
resistant strains have between 3% and 12% fitness loss 
compared to the wild type. 23 This level of fitness deficit 
rapidly allows the mutant to become dominant in vivo 
and yet allows the wild-type strain to out-compete the 
resistant strain once the selective pressure from the drug 
is removed.24 It must be remembered that, for most of 
Acyclovir: mechanism of action 
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their replication, resistant strains co-exist with wild-type 
ones, so that cell culture assays may preferentially detect 
wild-type virus after passage in vitro in the absence of 
drug. However, by the time CMV end-organ disease has 
become established, resistant strains may be so domin- 
ant that they can be detected by cell culture, and a 
recent report found them in 20% of recipients of solid 
organ transplants with CMV disease.25 The concordance 
between these two clinicopathological studies22,25 shows 
that CMV resistance to ganciclovir is more common 
than was thought previously and should be integrated 
into treatment protocols. In addition, knowledge of the 
dynamics of CMV replication has allowed the efficacy of 
antiviral drugs in vivo to be predicted.24 This shows that 
intravenous ganciclovir is sufficiently potent to control 
CMV replication, in contrast to oral ganciclovir which 
only delays the appearance of high viral loads of CMV 
and thereby selects for strains resistant to ganciclovir.24 
Selection for resistance could therefore be reduced if 
the valganciclovir prodrug was used in preference to 
oral ganciclovir. 
Although laboratory assays to detect resistant 
strains of CMV are found only in specialized research 
laboratories, all laboratories monitoring patients by 
polymerase chain reaction or antigenemia should 
discuss with their clinical colleagues the possibility of 
resistance when viraemia fails to disappear during intra- 
venous ganciclovir administration. Furthermore, if 
viraemia appears during long-term ganciclovir mainten- 
ance therapy, the chance of resistance is high, there- 
fore, as long as the patient’s compliance has been 
good, treatment should be swapped to foscarnet 
pending receipt of the results of resistance testing. 
HEPATITIS B: LAMIVUDINE 
Infection with hepatitis B virus (HBV) is widespread 
in the world, maintained by perinatal transmission, 
horizontal transfer during childhood and sexual 
acquisition. In addition, reactivation of HBV after cyto- 
toxic or immunosuppressive therapy is also becoming 
increasingly recognized. 26 Most infections are chronic 
and initially asymptomatic, although years of virus repli- 
cation finally lead to chronic active hepatitis, cirrhosis 
and primary liver cell cancer.27 Hepatitis B virus persists 
in cells as a covalently closed circular genome which acts 
as a template for HBV RNA. This replicative intermedi- 
ate is then copied into DNA, which is packaged into new 
virions. The covalently closed circular form is main- 
tained by cellular enzymes, and antiviral drugs have no 
direct effect, so it can be thought of as analogous to the 
latent genome of HSV. In contrast, expression of the 
genome requires reverse transcriptase and DNA poly- 
merase enzymic functions of its polymerase gene, which 
are the biochemical steps inhibited by antiviral drugs. 
The drugs employed are activated solely by host 
enzymes; the small HBV genome does not encode 
enzymes analogous to the Tk of HSV, so that drug 
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selectivity resides entirely at the level of the DNA 
polymerase. 
Famciclovir has low level activity against HBV, but 
has been superseded by the more potent lamivudine. 
Lamivudine is a nucleoside compound, which is activated 
by cellular enzymes to its triphosphate, which then acts 
as a potent inhibitor of reverse transcriptase. Long-term 
therapy (for several months) is required to suppress 
HBV and it is therefore not surprising that resistant 
mutants emerge under this selective pressure. There is 
some evidence that these mutants have reduced fitness 
because they may disappear when lamivudine therapy 
is stopped,28 implying that a policy of continuing 
lamivudine may be appropriate, especially as rebound 
hepatitis may occur when the drug is withdrawn.2g 
Clinical trials show a moderate effect of lamivudine 
in controlling HBV replication. While this effect is 
superior to that of interferon-alpha, it is still inadequate 
to control HBV completely, in view of the frequent 
rebound in HBV DNA when lamivudine is stopped or, 
indeed, during chronic treatment.2g Resistance clearly 
contributes to this treatment failure and mutations in 
codon 550 are mostly responsible. These changes are 
directly analogous to those found in the reverse tran- 
scriptase of HIV when lamivudine is employed, and 
involve changes in a conserved YMDD active site motif, 
where the methionine is changed to either isoleucine or 
to valine (MSSOV/I). By analogy with HIV, these mutants 
may show increased fidelity as a result of reduced 
pyrophosphorolysis (the reverse reaction of nucleotide 
polymerization) and decreased processivity.30 A second 
mutation (L526M) is sometimes present in addition to 
changes at codon 550 and confers cross-resistance to 
famcyclovir. 
Clinical trials are underway with more potent 
compounds, such as adefovir, entecavir or emtricitabine, 
and other compounds are at the pre-clinical and phase 
I levels of testing. It will be important to determine the 
degree of cross-resistance between these compounds 
and study the fitness of mutant viruses that emerge. 
Current evidence suggests that the 550 mutants remain 
sensitive to adefovir but may confer cross-resistance to 
many L-nucleoside compounds.30 A recent open, clinical 
trial of adefovir reported evidence of activity against 
lamivudine-resistant HBV31 Future approaches of com- 
bination therapy analogous to HIV seem likely, raising 
the potential problems of drug interactions and cross- 
resistance. Furthermore, HBV is an important oppor- 
tunistic infection in AIDS patients, which is increasing in 
importance now that HAART has dramatically reduced 
mortality resulting from HIV itself.32 The difficulties 
of giving anti-hepatitis B chemotherapy to patients 
who are co-infected with HIV should not be under- 
estimated;33 indeed, HBV resistance has been recorded 
in patients co-infected with HBV/HIV when lamivudine 
was used as one component of a HAART regimen.34 
INFLUENZA VIRUS: RIMANTADINEI 
NEURAMINIDASE INHIBITORS 
Influenza virus is a major pathogen, responsible for 
substantial excess mortality during some winters.35 The 
virus can be inhibited using drugs that act on the M2 
gene product (rimantadine or amantadine) or those that 
are direct inhibitors of the virus-encoded neuraminidase 
(zanamivir or oseltamivir). The M2 gene encodes an ion 
channel that pumps protons thus reducing acidification 
of post-Golgi compartments, which would otherwise 
lead to premature cleavage of the haemagglutinin pre- 
cursor before this glycoprotein reaches the virus 
envelope. The M2 protein is also involved at the input 
stage when the virus is in the lysosome, where it helps 
fusion of the lysosomal/viral envelope membranes, 
allowing the viral genome to reach the cytoplasm. 
Early clinical trials of rimantadine showed that this 
drug could accelerate the recovery of patients with 
influenza infection. It was also shown that rimantadine 
was better than placebo at preventing influenza among 
household contacts of an index case. However, when 
rimantadine was given to both the index case and family 
members, it was no better than placebo under these new 
circumstances. Investigations showed that influenza 
virus rapidly becomes resistant to rimantadine and that 
treated index cases were transmitting resistant strains to 
household members, thus rendering their prophylaxis 
ineffective.36 This observation shows that resistant 
strains of influenza are selected rapidly and that they 
appear to have full clinical virulence. By extrapolation, 
it implies that hospitals should not both treat patients 
with influenza and give prophylaxis to their own staff 
members; a situation that requires thoughtful consider- 
ation on both ethical and scientific grounds by infection 
control committees. It is fortunate, therefore, that a new 
class of drugs, active against a different target in influ- 
enza, has recently become available. 
The haemagglutinin of influenza binds to a sialic 
acid receptor on the cell surface to begin the process of 
virus entry. However, once the cell has formed daughter 
virions, they become trapped on the cell surface through 
these same interactions. Influenza decreases this effect 
by using neuraminidase to cleave the cellular sialic acid, 
thereby releasing new virus into the extracellular fluid. 
Inhibitors of neuraminidase should therefore greatly 
reduce the viral load of influenza. The neuraminidase 
inhibitors are poorly bioavailable so zanamivir is admin- 
istered by inhalation, whereas oseltamivir is a prodrug 
that is absorbed and then cleaved to reveal the authentic 
inhibitor of neuraminidase. Both drugs are therefore 
novel examples of antivirals that work extracellularly. 
The clinical studies that have been conducted to date 
show that resistance is far less of a problem than was 
found with rimantadine. In order to detect strains of 
influenza resistant to neuraminidase inhibitors, novel 
methods have been developed.37 The standard plaque 
reduction assay cannot be used because of the variable 
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ability of influenza to plaque in cell cultures, together 
with its cell-to-cell spread. As a result, direct measure- 
ment of neuraminidase activity is employed to detect 
resistant strains. It should also be noted that the effect 
of neuraminidase inhibition can be partially bypassed by 
a reduced affinity haemagglutinin, decreasing the need 
for neuraminidase to allow viral egress from the cell 
surface. To date, only rare cases of resistance to these 
new drugs have been described. Typically, they have 
been detected in immunocompromised individuals 
(who can be predicted to have higher viral loads and 
longer duration of virus excretion). Individual cases of 
mutations in the neuraminidase and/or haemagglutinin 
genes have been described.37 Interestingly, the mutant 
viruses show reduced catalytic activity of the neura- 
minidase, consistent with their preferential detection in 
individuals with compromised immunity. 
Overall, the availability of neuraminidase inhibitors 
is a very welcome development, given the high morbidity 
and mortality associated with influenza. However, there 
are practical difficulties in delivering these compounds 
to individuals who would benefit most; so many diffi- 
culties in fact that it may lead to a change in prescribing 
practice. Specifically, the prescribing of these safe 
compounds may be devolved to alternative prescribers 
such as a pharmacist or a nurse and perhaps only made 
available when influenza has been proven in the local 
area and supported in due course with rapid dipstick- 
type viral diagnostic methods.38 This laudable attempt to 
reduce the morbidity and mortality of influenza may 
facilitate the development of resistance so we should 
remain vigilant and encourage enhanced surveillance 
for resistant strains. 
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